Exact Sciences Corporation (EXAS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Exact Sciences Corporation (EXAS) trades at $104.91 with AI Score 62/100 (Grade B+). Exact Sciences Corporation specializes in cancer screening and diagnostic tests, with a focus on early detection. Market cap: $20.03B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026EXAS stock analysis for 2026: Analysts have set a consensus price target of $105.00 for Exact Sciences Corporation, suggesting 0.1% upside from the current price of $104.91. The AI MoonshotScore is 62/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
EXAS: 1/4 perspectives are bullish.
How is this calculated? →Exact Sciences Corporation (EXAS) Healthcare & Pipeline Overview
Exact Sciences Corporation is a leading provider of cancer screening and diagnostic solutions, primarily known for its non-invasive Cologuard test for colorectal cancer. With a focus on early detection and personalized medicine, the company competes in the evolving landscape of molecular diagnostics and precision oncology.
What Is the Investment Thesis for EXAS?
Exact Sciences Corporation presents a compelling investment case centered on its leadership in non-invasive cancer screening and personalized diagnostics. The company's primary value driver is the continued adoption and market penetration of Cologuard, which offers a convenient and effective alternative to traditional colon cancer screening methods. With a gross margin of 69.7%, Cologuard's profitability contributes significantly to the company's financial performance. Growth catalysts include expanding the eligible screening population, increasing physician awareness, and improving the test's specificity and sensitivity through ongoing research and development. The company's pipeline of blood-based cancer screening tests represents a significant long-term growth opportunity. However, potential risks include competition from alternative screening methods, changes in reimbursement policies, and the successful execution of its pipeline development programs. The company's beta of 1.44 indicates higher volatility compared to the overall market.
Based on FMP financials and quantitative analysis
EXAS Key Highlights
- Market capitalization of $20.03B, reflecting investor confidence in the company's growth prospects and market leadership.
- Gross margin of 69.7%, indicating strong pricing power and efficient cost management in its diagnostic testing services.
- Cologuard, the flagship product, drives revenue growth through increased adoption and market penetration in colorectal cancer screening.
- Strategic collaborations with Mayo Foundation and Hologic, Inc. enhance research and development capabilities and expand market reach.
- Focus on personalized medicine through Oncotype DX suite of gene expression tests, guiding treatment decisions for various cancers.
Who Are EXAS's Competitors?
EXAS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | $189.31 | +0.04% | $40.25B | 56 |
| ROIV Roivant Sciences Ltd. | $35.39 | +0.74% | $25.45B | 39 |
| VTRS Viatris Inc. | $16.80 | +0.60% | $19.56B | 33 |
| BBIO BridgeBio Pharma, Inc. | $79.19 | +2.60% | $15.51B | — |
| SMMT Summit Therapeutics Inc. | $15.64 | +1.45% | $12.14B | 46 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EXAS's Key Strengths?
- Leading position in non-invasive colorectal cancer screening with Cologuard.
- Personalized medicine offerings with Oncotype DX.
- Strong brand recognition and established market presence.
- Strategic collaborations with Mayo Foundation and Hologic.
What Are EXAS's Weaknesses?
- Negative profit margin of -6.4%.
- Reliance on Cologuard for a significant portion of revenue.
- Competition from established screening methods and emerging diagnostic technologies.
- Dependence on reimbursement policies and regulatory approvals.
What Could Drive EXAS Stock Higher?
- Data releases from ongoing clinical trials evaluating the performance of blood-based cancer screening tests.
- Continued expansion of Cologuard's market reach through increased awareness and adoption.
- Expansion of the Oncotype DX platform into new cancer types and applications.
- Potential regulatory approvals for new diagnostic tests and technologies.
What Are the Key Risks for EXAS?
- Negative return on equity (-8.5%) — the business is not currently generating profit on shareholder capital.
- Insider selling — insiders were net sellers of roughly $24.5M recently.
- Competition from established screening methods and emerging diagnostic technologies.
- Changes in reimbursement policies that could reduce the price or coverage of Cologuard.
- Failure to successfully develop and commercialize new diagnostic tests.
- Dependence on the success of Cologuard for a significant portion of revenue.
- Adverse regulatory actions or product recalls.
What Are the Growth Opportunities for EXAS?
- Expanding Cologuard's Market Reach: Exact Sciences has the opportunity to further penetrate the colorectal cancer screening market by increasing awareness among physicians and patients. The addressable market includes the unscreened population aged 45 and older, representing a significant growth opportunity. By improving the test's specificity and sensitivity through ongoing research and development, Exact Sciences can enhance its competitive advantage and drive further adoption. The company can also explore partnerships with healthcare providers and insurers to expand access to Cologuard and improve screening rates.
- Developing Blood-Based Cancer Screening Tests: Exact Sciences is investing in the development of blood-based cancer screening tests for multiple cancer types. These tests have the potential to revolutionize cancer detection by offering a convenient and cost-effective alternative to traditional screening methods. The market for blood-based cancer screening is estimated to be worth billions of dollars, and Exact Sciences is well-positioned to capture a significant share of this market. Successful development and commercialization of these tests could significantly expand the company's revenue streams and drive long-term growth.
- Personalized Medicine with Oncotype DX: The Oncotype DX suite of gene expression tests provides personalized genomic information to guide treatment decisions for breast, prostate, and colon cancers. Exact Sciences can expand the use of Oncotype DX by increasing awareness among oncologists and patients and by demonstrating the clinical and economic value of these tests. The company can also develop new Oncotype DX tests for other cancer types, further expanding its market reach and solidifying its position in personalized medicine.
- International Expansion: Exact Sciences has the opportunity to expand its geographic reach by commercializing its products in international markets. Colorectal cancer is a global health problem, and there is a significant unmet need for effective screening solutions in many countries. By partnering with local distributors and healthcare providers, Exact Sciences can access new markets and drive international growth. The company can also adapt its products to meet the specific needs and regulatory requirements of different countries.
- Strategic Acquisitions and Partnerships: Exact Sciences can pursue strategic acquisitions and partnerships to expand its product portfolio, enhance its research and development capabilities, and accelerate its growth. The company can acquire complementary diagnostic companies or technologies to broaden its offerings and strengthen its competitive position. Partnerships with academic institutions and research organizations can provide access to new biomarkers and technologies, accelerating the development of innovative diagnostic solutions.
What Opportunities Does EXAS Have?
- Expanding Cologuard's market reach to the unscreened population.
- Developing blood-based cancer screening tests for multiple cancer types.
- Expanding the use of Oncotype DX in personalized medicine.
- International expansion to new geographic markets.
What Threats Does EXAS Face?
- Competition from alternative screening methods, such as colonoscopy and fecal immunochemical tests (FIT).
- Changes in reimbursement policies that could reduce the price or coverage of Cologuard.
- Failure to successfully develop and commercialize new diagnostic tests.
- Adverse regulatory actions or product recalls.
What Are EXAS's Competitive Advantages?
- Proprietary technology and intellectual property related to Cologuard and Oncotype DX.
- Established market position and brand recognition in the colorectal cancer screening market.
- Extensive network of healthcare providers and payers.
- Strong research and development capabilities and a pipeline of innovative diagnostic solutions.
What Does EXAS Do?
Exact Sciences Corporation, founded in 1995 and headquartered in Madison, Wisconsin, is a molecular diagnostics company focused on the early detection and prevention of various cancers. The company's flagship product, Cologuard, is a non-invasive, stool DNA screening test for colorectal cancer, designed to detect both DNA and hemoglobin biomarkers associated with the disease and pre-cancerous polyps. Cologuard offers an alternative to traditional screening methods, aiming to improve patient compliance and early detection rates. Beyond Cologuard, Exact Sciences offers the Oncotype DX suite of gene expression tests, which provide personalized genomic information to guide treatment decisions for breast, prostate, and colon cancers. These tests analyze the activity of specific genes within a tumor to predict the likelihood of recurrence and response to chemotherapy. The company also provides the Oncotype Test, a tissue-based assay for advanced cancers, and the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy for advanced prostate cancer. In addition, Exact Sciences offers Oncomap ExTra, a comprehensive genomic profiling service for refractory, rare, or aggressive cancers. The company also offers Covid-19 testing services. Exact Sciences has strategic collaborations and license agreements with institutions like the MAYO Foundation for Medical Education and Research and Hologic, Inc., to further develop and commercialize its diagnostic technologies. The company operates both domestically in the United States and internationally.
What Products and Services Does EXAS Offer?
- Develops and commercializes non-invasive cancer screening tests.
- Offers Cologuard, a stool-based DNA test for colorectal cancer screening.
- Provides Oncotype DX gene expression tests for breast, prostate, and colon cancers.
- Offers tissue-based assays for advanced cancers to guide therapy selection.
- Develops blood-based cancer screening tests for multiple cancer types.
- Provides Covid-19 testing services.
How Does EXAS Make Money?
- Generates revenue through the sale of Cologuard screening tests to healthcare providers and patients.
- Earns revenue from Oncotype DX gene expression tests, which provide personalized genomic information for cancer treatment decisions.
- Receives reimbursement from insurance companies and government payers for its diagnostic testing services.
- Forms strategic collaborations and license agreements with other companies to develop and commercialize its products.
What Industry Does EXAS Operate In?
Exact Sciences Corporation operates within the medical diagnostics and research industry, which is experiencing rapid growth driven by technological advancements, increasing cancer prevalence, and a growing emphasis on early detection and personalized medicine. The market for cancer diagnostics is highly competitive, with companies like RVMD: Revolution Medicines, Inc. and ROIV: Roivant Sciences Ltd. developing innovative screening and diagnostic solutions. The industry is also subject to stringent regulatory requirements and evolving reimbursement policies. Exact Sciences differentiates itself through its non-invasive Cologuard test and its focus on personalized genomic information through the Oncotype DX suite.
Who Are EXAS's Key Customers?
- Healthcare providers, including primary care physicians and gastroenterologists.
- Patients who are eligible for colorectal cancer screening.
- Oncologists who treat patients with breast, prostate, and colon cancers.
- Hospitals and cancer centers that offer diagnostic testing services.
Net sellingInsider Activity
Over the past six months, Exact Sciences Corporation insiders filed 30 SEC Form 4 transactions — 25 sales and 5 purchases. On net that is roughly 618K shares disposed (about $24.5M), a signal worth weighing alongside the fundamentals.
EXAS Valuation & Market Position
With a $20.03B market cap, Exact Sciences Corporation sits in the large-cap segment of the market. Relative to its peer group, EXAS's quantitative score of 62/100 is above the peer average of 44/100.
ROE -9%Key Financial Metrics
Return on equity for Exact Sciences Corporation stands at -8.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Exact Sciences Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.97 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Exact Sciences Corporation revenue of about $3.69B for fiscal 2026, with EPS near $0.18. The estimate reflects 9 contributing analysts.
Company Profile
Exact Sciences Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Madison, US. The company is led by CEO Kevin T. Conroy. EXAS has traded publicly since 2001.
EXAS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, mirroring situations like Netflix insiders buying before subscriber growth surprises.
- The community is buzzing about potential new partnerships, creating a positive feedback loop similar to what fueled Palantir's early growth.
- There's a strong belief that upcoming product launches will significantly expand their market reach, much like Apple's product releases.
- The overall market sentiment seems to be shifting towards preventative healthcare, benefiting companies like Exact Sciences, similar to the rise of telehealth during the pandemic.
Bear Case
- Some insiders have been quietly reducing their positions, which can sometimes signal concerns about long-term growth, like executives selling Facebook stock after peak growth.
- The community is expressing worries about increased competition in the diagnostic testing space, similar to the challenges faced by Fitbit in the wearables market.
- There's growing concern that reimbursement rates from insurers might be lower than expected, impacting profitability, reminiscent of the pricing pressure faced by generic drug manufacturers.
- Market perception is leaning towards caution due to recent regulatory hurdles faced by similar companies in the healthcare sector, like the FDA scrutiny of certain medical devices.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EXAS Latest News
-
Earnings Scheduled For August 6, 2025
benzinga · Aug 6, 2025
-
Earnings Scheduled For May 1, 2025
benzinga · May 1, 2025
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Oct 12, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Oct 11, 2022
EXAS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EXAS.
Price Targets
Consensus target: $105.00
EXAS MoonshotScore
What does this score mean?
The MoonshotScore rates EXAS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kevin T. Conroy
Chairman and Chief Executive Officer
Kevin Conroy has served as the Chairman and Chief Executive Officer of Exact Sciences since 2009. Prior to joining Exact Sciences, he served as President and CEO of Third Wave Technologies, Inc., a molecular diagnostics company, from 2003 until its acquisition by Hologic in 2008. He also held various leadership positions at Cytyc Corporation and Genzyme Corporation. Conroy holds a J.D. from the University of Michigan Law School and a B.S. in Electrical and Computer Engineering from the University of Michigan.
Track Record: Under Kevin Conroy's leadership, Exact Sciences has transformed from a small biotechnology company into a leading provider of cancer screening and diagnostic solutions. He spearheaded the development and commercialization of Cologuard, which has become a widely adopted non-invasive screening test for colorectal cancer. Conroy has also overseen the acquisition of Genomic Health, expanding Exact Sciences' portfolio of personalized medicine offerings. During his tenure, the company's revenue has grown significantly, and its market capitalization has increased substantially.
Exact Sciences Corporation Healthcare Stock: Key Questions Answered
What does Exact Sciences Corporation do?
Exact Sciences Corporation is a molecular diagnostics company specializing in the development and commercialization of cancer screening and diagnostic tests. Its primary product is Cologuard, a non-invasive stool DNA screening test for colorectal cancer, designed to detect both DNA and hemoglobin biomarkers associated with the disease. The company also offers the Oncotype DX suite of gene expression tests, which provide personalized genomic information to guide treatment decisions for breast, prostate, and colon cancers. Exact Sciences aims to improve early cancer detection and personalized treatment through its innovative diagnostic solutions.
What do analysts say about EXAS stock?
Analyst consensus on Exact Sciences Corporation (EXAS) reflects a generally positive outlook, driven by the continued growth of Cologuard and the potential of its pipeline of blood-based cancer screening tests. Key valuation metrics include the company's market capitalization and revenue growth rate. Analysts consider the company's ability to expand its market share in colorectal cancer screening and to successfully develop and commercialize new diagnostic tests as key growth drivers. However, they also note the risks associated with competition, reimbursement policies, and regulatory approvals. Analyst ratings and price targets vary, reflecting different perspectives on the company's future prospects.
What are the main risks for EXAS?
Exact Sciences Corporation faces several key risks, including competition from established screening methods like colonoscopy and emerging diagnostic technologies. Changes in reimbursement policies could negatively impact the price and coverage of Cologuard, affecting revenue. The company's reliance on Cologuard for a significant portion of its revenue makes it vulnerable to market shifts. The successful development and commercialization of new diagnostic tests are crucial for long-term growth, and failures in this area could hinder the company's prospects. Adverse regulatory actions or product recalls could also pose significant risks.
What are the key factors to evaluate for EXAS?
Exact Sciences Corporation (EXAS) holds an AI score of 62/100 (moderate). Analysts target $105.00 (+0%). Not financial advice.
How frequently does EXAS data refresh on this page?
EXAS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EXAS's recent stock price performance?
Exact Sciences Corporation (EXAS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading position in non-invasive colorectal cancer screening with Cologuard. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EXAS overvalued or undervalued right now?
Valuing Exact Sciences Corporation (EXAS) requires multiple metrics. Analysts target $105.00 (+0%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EXAS?
Before investing in Exact Sciences Corporation (EXAS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the latest available reporting period.